New York Life Investment Management LLC Raises Position in Pfizer Inc. $PFE

New York Life Investment Management LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 801,371 shares of the biopharmaceutical company’s stock after acquiring an additional 16,995 shares during the quarter. New York Life Investment Management LLC’s holdings in Pfizer were worth $19,425,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. Pavion Blue Capital LLC boosted its stake in shares of Pfizer by 8.8% during the 2nd quarter. Pavion Blue Capital LLC now owns 9,787 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 788 shares during the last quarter. Howard Capital Management Inc. lifted its stake in shares of Pfizer by 8.4% during the 2nd quarter. Howard Capital Management Inc. now owns 148,309 shares of the biopharmaceutical company’s stock valued at $3,595,000 after buying an additional 11,445 shares in the last quarter. Reliant Investment Partners LLC lifted its stake in shares of Pfizer by 4.3% during the 2nd quarter. Reliant Investment Partners LLC now owns 29,210 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 1,198 shares in the last quarter. Wincap Financial LLC lifted its stake in shares of Pfizer by 6.8% during the 2nd quarter. Wincap Financial LLC now owns 42,289 shares of the biopharmaceutical company’s stock valued at $1,025,000 after buying an additional 2,699 shares in the last quarter. Finally, First National Trust Co lifted its stake in shares of Pfizer by 0.4% during the 2nd quarter. First National Trust Co now owns 165,789 shares of the biopharmaceutical company’s stock valued at $4,019,000 after buying an additional 703 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.76 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $140.75 billion, a P/E ratio of 13.17, a P/E/G ratio of 0.82 and a beta of 0.55. The firm’s fifty day moving average is $24.86 and its two-hundred day moving average is $24.21. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s payout ratio is 91.49%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PFE. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.